CLENE INC (CLNN) Stock Fundamental Analysis

NASDAQ:CLNN • US1856342019

4.74 USD
+0.22 (+4.87%)
At close: Feb 19, 2026
4.05 USD
-0.69 (-14.56%)
After Hours: 2/12/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, CLNN scores 2 out of 10 in our fundamental rating. CLNN was compared to 521 industry peers in the Biotechnology industry. CLNN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CLNN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CLNN has reported negative net income.
  • CLNN had a negative operating cash flow in the past year.
  • CLNN had negative earnings in each of the past 5 years.
  • In the past 5 years CLNN always reported negative operating cash flow.
CLNN Yearly Net Income VS EBIT VS OCF VS FCFCLNN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -136.69%, CLNN is doing worse than 81.96% of the companies in the same industry.
Industry RankSector Rank
ROA -136.69%
ROE N/A
ROIC N/A
ROA(3y)-101.99%
ROA(5y)-69.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLNN Yearly ROA, ROE, ROICCLNN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

1.3 Margins

  • Looking at the Gross Margin, with a value of 82.24%, CLNN belongs to the top of the industry, outperforming 86.56% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CLNN has grown nicely.
  • CLNN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.02%
GM growth 5YN/A
CLNN Yearly Profit, Operating, Gross MarginsCLNN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • CLNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CLNN has more shares outstanding than it did 1 year ago.
  • CLNN has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CLNN has a worse debt to assets ratio.
CLNN Yearly Shares OutstandingCLNN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLNN Yearly Total Debt VS Total AssetsCLNN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • CLNN has an Altman-Z score of -21.26. This is a bad value and indicates that CLNN is not financially healthy and even has some risk of bankruptcy.
  • CLNN's Altman-Z score of -21.26 is on the low side compared to the rest of the industry. CLNN is outperformed by 84.07% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -21.26
ROIC/WACCN/A
WACC9.95%
CLNN Yearly LT Debt VS Equity VS FCFCLNN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

  • A Current Ratio of 1.53 indicates that CLNN should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.53, CLNN is not doing good in the industry: 80.81% of the companies in the same industry are doing better.
  • CLNN has a Quick Ratio of 1.52. This is a normal value and indicates that CLNN is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of CLNN (1.52) is worse than 79.85% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 1.52
CLNN Yearly Current Assets VS Current LiabilitesCLNN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 32.20% over the past year.
  • Looking at the last year, CLNN shows a very negative growth in Revenue. The Revenue has decreased by -49.17% in the last year.
  • Measured over the past years, CLNN shows a very negative growth in Revenue. The Revenue has been decreasing by -21.98% on average per year.
EPS 1Y (TTM)32.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.33%
Revenue 1Y (TTM)-49.17%
Revenue growth 3Y-21.98%
Revenue growth 5YN/A
Sales Q2Q%-82.76%

3.2 Future

  • Based on estimates for the next years, CLNN will show a very strong growth in Earnings Per Share. The EPS will grow by 24.58% on average per year.
  • CLNN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 304.58% yearly.
EPS Next Y60.08%
EPS Next 2Y27.66%
EPS Next 3Y22.74%
EPS Next 5Y24.58%
Revenue Next Year-57.73%
Revenue Next 2Y-12.27%
Revenue Next 3Y483.93%
Revenue Next 5Y304.58%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLNN Yearly Revenue VS EstimatesCLNN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
CLNN Yearly EPS VS EstimatesCLNN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 -10 20

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CLNN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLNN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLNN Price Earnings VS Forward Price EarningsCLNN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLNN Per share dataCLNN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CLNN's earnings are expected to grow with 22.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.66%
EPS Next 3Y22.74%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CLNN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CLENE INC

NASDAQ:CLNN (2/19/2026, 2:49:35 PM)

After market: 4.05 -0.69 (-14.56%)

4.74

+0.22 (+4.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-23
Inst Owners13.9%
Inst Owner Change19.3%
Ins Owners19.84%
Ins Owner Change0.38%
Market Cap51.43M
Revenue(TTM)214.00K
Net Income(TTM)-30.50M
Analysts81.54
Price Target32.49 (585.44%)
Short Float %10.66%
Short Ratio4.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-52.62%
Min EPS beat(2)-61.56%
Max EPS beat(2)-43.68%
EPS beat(4)1
Avg EPS beat(4)-26.62%
Min EPS beat(4)-91.95%
Max EPS beat(4)90.71%
EPS beat(8)4
Avg EPS beat(8)-7.25%
EPS beat(12)6
Avg EPS beat(12)-1.71%
EPS beat(16)9
Avg EPS beat(16)12.69%
Revenue beat(2)0
Avg Revenue beat(2)-61.61%
Min Revenue beat(2)-73.33%
Max Revenue beat(2)-49.89%
Revenue beat(4)1
Avg Revenue beat(4)-28.67%
Min Revenue beat(4)-73.33%
Max Revenue beat(4)39.93%
Revenue beat(8)2
Avg Revenue beat(8)-19.69%
Revenue beat(12)4
Avg Revenue beat(12)1.91%
Revenue beat(16)6
Avg Revenue beat(16)9%
PT rev (1m)0%
PT rev (3m)4.69%
EPS NQ rev (1m)-5.27%
EPS NQ rev (3m)-9.68%
EPS NY rev (1m)0%
EPS NY rev (3m)-18.02%
Revenue NQ rev (1m)-26.02%
Revenue NQ rev (3m)-37.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-33.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 240.32
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.58
EYN/A
EPS(NY)-2.2
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0.02
BVpS-1.14
TBVpS-1.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -136.69%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.24%
FCFM N/A
ROA(3y)-101.99%
ROA(5y)-69.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.02%
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.78%
Cap/Sales 5.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 1.52
Altman-Z -21.26
F-Score3
WACC9.95%
ROIC/WACCN/A
Cap/Depr(3y)176.04%
Cap/Depr(5y)141.46%
Cap/Sales(3y)385.66%
Cap/Sales(5y)305.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.33%
EPS Next Y60.08%
EPS Next 2Y27.66%
EPS Next 3Y22.74%
EPS Next 5Y24.58%
Revenue 1Y (TTM)-49.17%
Revenue growth 3Y-21.98%
Revenue growth 5YN/A
Sales Q2Q%-82.76%
Revenue Next Year-57.73%
Revenue Next 2Y-12.27%
Revenue Next 3Y483.93%
Revenue Next 5Y304.58%
EBIT growth 1Y29.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.45%
EBIT Next 3Y0.21%
EBIT Next 5Y44.83%
FCF growth 1Y43.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.39%
OCF growth 3YN/A
OCF growth 5YN/A

CLENE INC / CLNN FAQ

What is the fundamental rating for CLNN stock?

ChartMill assigns a fundamental rating of 2 / 10 to CLNN.


Can you provide the valuation status for CLENE INC?

ChartMill assigns a valuation rating of 1 / 10 to CLENE INC (CLNN). This can be considered as Overvalued.


What is the profitability of CLNN stock?

CLENE INC (CLNN) has a profitability rating of 1 / 10.


Can you provide the financial health for CLNN stock?

The financial health rating of CLENE INC (CLNN) is 1 / 10.